Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 12/20 | 0.93 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | PKM | P14618 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | METAP2 | P50579 | 8/20 | 0.60 |
| ▸ | METAP1 | P53582 | 6/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
| ▸ | F7 | P08709 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125153 | 0.91 | CBFB (1.00) | CBFBNPC1PKMRAB9ALMNA | |
| SCHEMBL13866537 | 0.79 | NPC1 (0.81) | CBFBNPC1PKMRAB9ALMNA | |
| SCHEMBL32660767 | 0.77 | CBFB (1.00) | CBFBNPC1PKMRAB9ALMNA | |
| SCHEMBL32660737 | 0.77 | CBFB (0.80) | CBFBNPC1PKMRAB9ALMNA | |
| SCHEMBL5032550 | 0.77 | CBFB (1.00) | CBFBNPC1PKMRAB9ALMNA | |
| SCHEMBL125118 | 0.77 | CBFB (0.80) | CBFBNPC1PKMRAB9ALMNA | |
| SCHEMBL179149 | 0.77 | NPC1 (0.63) | CBFBNPC1PKMRAB9ALMNA | |
| SCHEMBL13223456 | 0.76 | NPC1 (1.00) | CBFBNPC1PKMRAB9ALMNA | |
| SCHEMBL4193380 | 0.76 | NPC1 (0.63) | CBFBNPC1PKMRAB9ALMNA | |
| SCHEMBL124391 | 0.75 | CBFB (0.78) | CBFBNPC1PKMRAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926290-B2 | Inhibitors of INV(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2016-04-07 | — | — | US | disclosed |
| US-9221764-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8748618-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CBFB 3/4885NPC1 1794/4885PKM 3188/4885 |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CBFB 3/4885NPC1 1798/4885PKM 3075/4885 |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CBFB 3/4885NPC1 1798/4885PKM 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.